Early High-Volume IV Fluids to Protect Kidneys in Children With Shiga Toxin-Producing E. Coli Infection A Randomized Multinational Trial
Led by University of Calgary · Updated on 2026-05-18
1040
Participants Needed
26
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether early, high-volume intravenous fluid administration hyperhydration can help reduce or prevent complications in children and adolescents infected with shiga toxin-producing Escherichia coli STEC, compared to traditional conservative fluid management. The study focuses on hemolytic uremic syndrome HUS, a serious complication of STEC infection that can cause acute kidney injury and other life-threatening effects. Despite low mortality, many affected children face long-term health issues, and previous trials have not proven effective treatments since 1999.
Participants are randomly assigned to one of two groups. The hyperhydration group receives intravenous fluids at 200% of maintenance for 24 hours, with adjustments based on hematocrit levels and weight gain, alongside allowed oral fluids. The conservative group follows current local practices, with fluid management decided by the clinical care team and admission based on specific lab evidence. This study also establishes a biorepository to explore biomarkers and potential treatments.
During the study, children are admitted for monitoring and receive fluid therapy according to their assigned group. Researchers assess kidney outcomes and serious complications over 30 days, focusing on major adverse kidney events including death, need for renal replacement therapy, or sustained kidney function loss. Safety and kidney health are closely monitored, with outcomes informing future care. The total participation time includes the initial treatment period and 30-day follow-up for outcome evaluation.
CONDITIONS
Brief Title
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
Research Team
S
Study Manager
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborating Sponsor
How This Trial Compares With Other Options
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Hyperhydration
Conservative fluid management
What it is
Early intravascular volume expansion using 200 % of maintenance IV fluids (balanced crystalloid) over 24 hours
Conservative fluid management using oral or IV fluids up to 110 % of maintenance
Role in the trial
Investigational aggressive fluid strategy in crossover design
Standard reactive fluid management strategy in crossover design
Primary use
To test whether early aggressive IV fluids reduce major adverse kidney events (MAKE30) and HUS complications
To represent current reactive outpatient‑focused fluid care against which hyperhydration is compared
How it is given or performed
200 % maintenance balanced crystalloid IV infusion over 24 hours, with electrolytes or dextrose added as needed
Oral and/or IV fluids totaling up to 110 % of maintenance, methods determined by care team
Evidence status
No results yet; effectiveness remains under investigation
Reactive conservative fluids are widely used pending stronger evidence
Important risks
Risks of fluid overload or electrolyte imbalance requiring close monitoring
Risk of under‑hydration and progression to HUS if fluid is delayed
Important limitations
Crossover design may limit generalizability; protocol avoids patients with advanced HUS
Reactive conservative fluids may delay volume expansion when early expansion could be beneficial
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 9Months - 21Years
All Genders
Eligibility Criteria
You may qualify if you...
Aged 9.0 months to less than 21 years at the time of consent
Evidence of high-risk shiga toxin-producing E. coli infection defined by either bloody diarrhea within 7 days with positive STEC test, or presumptive hemolytic uremic syndrome with anemia, thrombocytopenia, and renal insufficiency, or positive STEC culture or toxin gene test for high-risk strains
You will not qualify if you...
Presence of advanced hemolytic uremic syndrome (hematocrit less than 30%, platelet count less than 150 x 10^3/mm3, and creatinine over 2.0 mg/dL)
Prior episode of hemolytic uremic syndrome or diagnosis of atypical HUS
Chronic disease limiting fluid volumes such as kidney, liver, heart, or lung disease
No urine output for more than 24 hours (anuria)
Hypoxemia requiring oxygen therapy
Hypertensive emergency
Diarrhea onset 10 days or more ago, or symptom onset over 10 days ago if no diarrhea
Known pregnancy
Language barriers impairing study conduct
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 30 days
Participants receive either hyperhydration with intravenous fluids or conservative fluid management to assess effects on kidney outcomes and complications.
Hospital admission and fluid administration with ongoing monitoring during treatment
Follow-up
Duration - Up to 30 days after treatment
Participants are monitored for major adverse kidney events and extrarenal complications through 30 days after treatment.
Follow-up visits as per clinical care
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Study of Complement Defects in Thrombotic Microangiopathy and Related Conditions Including Severe Hypertension Using the HMEC Test
Study of INM004 Treatment in Children Ages 9 Months to 17 Years With Hemolytic Uremic Syndrome Caused by Shiga Toxin-Producing E. coli
Early High-Volume IV Fluids to Protect Kidneys in Children With Shiga Toxin-Producing E. Coli Infection A Randomized Multinational Trial
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Hyperhydration to Improve Kidney Outcomes in Children with Shiga Toxin-Producing E. coli Infection: a multinational embedded cluster crossover randomized trial (the HIKO STEC trial).
Stephen B Freedman, David Schnadower, Myka Estes...